Developing a bio-artificial pancreas for type 1 and insulin-dependent type 2 diabetes and α-Klotho-based therapies for age-related diseases and anti-aging treatments through proprietary live-cell encapsulation technology.
Chronic diseases are expanding globally, placing unprecedented pressure on patients and healthcare systems worldwide.
Diabetes alone caused at least $1 TRILLION in health expenditure — a 338% increase over 17 years.i
At Avaí Bio, Inc. (OTC: AVAI), efforts are centered on transforming chronic disease treatment through protected, living-cell therapies that target insulin deficiency and longevity biology, with the goal of advancing more durable and autonomous therapeutic solutions.
Diabetes and age-related diseases continue to expand globally, placing significant pressure on patients and healthcare systems. Current treatments primarily manage symptoms—such as insulin replacement or disease-specific drug regimens—without restoring the body's underlying biological function. As key regulatory proteins decline with age and insulin-producing cells are lost, long-term disease progression remains a major unmet medical need.
Avaí Bio, Inc. (OTC: AVAI) is developing encapsulated, genetically engineered cell therapies designed to restore essential biological activity. Its bio-artificial pancreas program aims to enable continuous insulin production for diabetes, while its α-Klotho program focuses on sustained delivery of a longevity-associated protein linked to age-related decline. By combining engineered cell lines with advanced Cell-in-a-Box® encapsulation technology, the company is advancing durable, protected therapeutic platforms for large and growing markets.
Avaí Bio, Inc. (OTC: AVAI) operates at the intersection of large and rapidly expanding global healthcare markets.
Critical steps driving Avaí Bio's advancement toward clinical-stage biotechnology leadership.
Avaí Bio, Inc. (OTC: AVAI) is advancing innovative cell-based therapies targeting large and expanding global markets in diabetes and age-related disease. The company's strategy centers on restoring essential biological functions through engineered, living-cell platforms designed for sustained therapeutic delivery.
For diabetes, Avaí Bio and its joint venture partner SGAustria are developing a bio-artificial pancreas utilizing encapsulated insulin-producing cells. This program leverages Austrianova's Cell-in-a-Box® technology to protect transplanted cells while enabling continuous, glucose-responsive insulin release.
In parallel, Avaí Bio has partnered with Austrianova to advance therapies based on the "Longevity Protein" α-Klotho, a key regulator associated with aging biology and systemic health.
Through structured joint ventures and licensing agreements, Avaí Bio is building a protected, scalable cellular therapy platform positioned within high-growth healthcare sectors.
*See our Important Notice and Disclaimer below for a detailed discussion on compensation, risks, the risks associated with forward looking statements, the need to seek the advice of a professional investment advisor before investing, and more.
This name change marks a defining moment in the Company's evolution from a technology-focused entity to a dedicated biotechnology innovator at the forefront of cellular medicine. Avaí Bio more accurately reflects the Company's mission to advance therapies addressing unmet needs in diabetes management and age-related diseases. Through genetically engineered cell lines, advanced encapsulation technologies designed to shield cells from immune rejection, and strategic joint ventures, Avaí Bio is positioned to advance progress toward long-term biological restoration and improved healthy lifespan outcomes.”
*See our Important Notice and Disclaimer below for a detailed discussion on compensation, risks, the risks associated with forward looking statements, the need to seek the advice of a professional investment advisor before investing, and more.
“This landmark publication by Prof. Amir Lerman's team at Mayo Clinic provides compelling clinical evidence linking lower α-Klotho levels to cardiovascular disease progression and mortality. By encapsulating α-Klotho-producing cells with the proven Cell-in-a-Box® platform—already demonstrated as safe and effective in human cancer trials—Austrianova believes systemic α-Klotho levels can be meaningfully elevated, potentially influencing cardiovascular disease and other age-related conditions associated with Klotho deficiency.”
“An expanding body of scientific literature, including this Mayo Clinic study, highlights α-Klotho as a significant regulator of aging biology. The age-related decline in α-Klotho has been associated with multiple chronic conditions. Avaí Bio's encapsulated cell therapy approach is designed to support sustained α-Klotho delivery, targeting mechanisms linked to cardiovascular health and longevity.”
Avaí Bio is an emerging biotechnology company partnering with leading-edge biotech firms, universities, scientists, and clinicians to uncover innovative solutions for diverse healthcare challenges, driving the development of advanced therapies that improve patient outcomes and quality of life. Avaí's mission is to transform healthcare through cutting-edge cellular technology and protective live-cell encapsulation, reshaping how patients see their available treatment options
Avaí Bio currently has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an α-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments. Avaí has secured Joint Venture and Licensing Agreements to develop both cell lines.
Avaí Bio focuses on identifying genetically modified cell lines globally to tackle challenging diseases or medical conditions and then developing therapies that supply what a patient's body can no longer provide effectively. The success of these cell lines depends on their safe delivery into the body and the subsequent protection from the patient's immune system. To achieve this, Avaí Bio has teamed up with a cell encapsulation company utilizing cutting-edge encapsulation technology to shield these cells.
Identifying and developing targeted, cutting edge, cell-based treatments
Avaí Bio currently has two development programs in its cellular therapies pipeline, a diabetes development program and a α-Klotho protein development program. Avaí has secured Joint Venture and Licensing Agreements to develop both cell lines.
Developing a cell line that is genetically modified to produce, store and secrete insulin in type 1 and insulin-dependent type 2 diabetics.
Learn More
Developing a genetically modified cell line that overexpresses the production of the α-Klotho protein for age-related treatments and anti-aging therapies.
Learn MoreChris Winter has over thirty-five years of experience in the investment banking and commodities industries working on numerous private placements, public offerings, mergers and acquisitions. He has worked closely with several Western European clients, assisting them in entering public U.S. markets and capital funding projects. Chris held a Series 3 license in Commodities, as well as Series 7 and 63 licenses in Securities from 1987 to 1994. In 1995, he opened a private investment banking consulting firm that worked with several companies, domestically and abroad. He has participated in raising over $70,000,000.00 throughout his career. In addition to his consulting business, in 2003, Chris took the helm as an Officer and Director with Innovative Holdings Alliance, Inc. and its predecessor Companies where he worked with attorneys, accountants, and auditors as well as the applicable regulatory agencies. From the mid-1990's to present, Chris has worked directly with a wide variety of industries including communication transmission, electric generation and storage, gold and silver mining, multi-media, infomercials, health care and equipment, and banking to name a few.
Avant Technologies Completes Rebranding With Name Change to Avaí Bio and Launch of New Website
Read Full News
February 2026
Avaí Bio Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA Symposium
Read Full News
January 2026
Avaí Bio Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes Treatment
Read Full News
December 2025
Avaí Bio and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival
Read Full News
December 2025
Avaí Bio, Inc. (OTC: AVAI) is advancing a focused cell-based therapy platform targeting diabetes and age-related diseases. The company's strategy centers on restoring essential biological functions through engineered, living-cell technologies designed for sustained therapeutic delivery.
Through its diabetes program, developed with joint venture partner SGAustria, Avaí Bio is progressing a bio-artificial pancreas approach using encapsulated insulin-producing cells, intended to enable continuous, glucose-responsive insulin delivery.
In parallel, the company is advancing its α-Klotho "Longevity Protein" program in collaboration with Austrianova, utilizing Cell-in-a-Box® encapsulation technology to support controlled, long-term protein secretion.
Positioned within expanding diabetes, longevity, and cell therapy markets, Avaí Bio is building a structured, partnership-driven platform focused on scalable innovation and long-term value development.
*See our Important Notice and Disclaimer below for a detailed discussion on compensation, risks, the risks associated with forward looking statements, the need to seek the advice of a professional investment advisor before investing, and more.
i — https://diabetesatlas.org/
ii — https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
iii — https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing
iv — https://www.worldkidneyday.org/wp-content/uploads/2025/02/WKD-2025-policy-brief.pdf
v — https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-21851-z
vi — https://avaibio.com/diabetes
vii — https://www.biospace.com/cell-therapy-market-size
viii — https://www.datamintelligence.com/research-report/longevity-therapeutics-market
ix — https://avaibio.com/
Equiscreen, LLC research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on publicly available data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Furthermore, some of the content on this website may contain forward-looking statements found in information made publicly available by the companies we highlight. This forward looking information fits within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding future possible events, expected continual growth of a company, the potential value of its securities, and look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company’s actual results of operation. We therefore strongly encourage that you visit and review any and all financial information made publicly available by highlighted companies.
Any opinions expressed in Equiscreen, LLC reports, company profiles, or other investor relations materials and presentations are subject to change, are expressed and given as of the date of publication, and we disclaim any obligation to advise you of any change in any information contained herein. Equiscreen, LLC and its affiliates may buy and sell shares of securities or options and warrants of the companies mentioned on this website at any time.
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, Equiscreen, LLC, our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).
Stock market investing is inherently risky. Equiscreen, LLC and its affiliates are not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov. and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca. and/or the British Columbia Securities Commission (“BCSC”) at https://www.bcsc.bc.ca/.
Equiscreen, LLC has been compensated by Interactive Offers, LLC to engage in investor awareness services for Avaí Bio, Inc. (OTC: AVAI). AVAI is a client of Interactive Offers, LLC. A beneficial owner of Equiscreen, LLC is a minority stakeholder of Interactive Offers, LLC, owning less than 10%. Equiscreen, LLC and its affiliates are not affiliates or control persons of Interactive Offers, LLC. Equiscreen, LLC has been compensated $3,500 by Interactive Offers, LLC to engage in investor awareness services for Avaí Bio, Inc. (OTC: AVAI). Equiscreen and its affiliated entities and partners have been compensated a total of $6,500 related to the engagement of investor awareness services for AVAI. Equiscreen, LLC and its partners and affiliates may buy and sell shares of securities or options and warrants of the companies mentioned on this website at any time.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. of Equiscreen, LLC investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services based on the publicly available information of our clients and prepared by our partners.
